The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 5.38 is strong.
Longduoduo Co has a Altman Z-Score of 5.38, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Longduoduo Co's Altman Z-Score or its related term are showing as below:
LDDD'
s Altman Z-Score Range Over the Past 10 Years
Min: 5.38 Med: 93.31 Max: 555.83
Current: 5.38
During the past 5 years, Longduoduo Co's highest Altman Z-Score was 555.83. The lowest was 5.38. And the median was 93.31.
Longduoduo Co (OTCPK:LDDD) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Longduoduo Co Altman Z-Score Related Terms
Longduoduo Co Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Longduoduo Co's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LDDD vs AWHL, BIAF, MBAI: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Longduoduo Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longduoduo Co Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Longduoduo Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Longduoduo Co's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Longduoduo Co's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.287
+
1.4
*
-3.8222
+
3.3
*
-0.1292
+
0.6
*
15.9958
+
1.0
*
1.2184
=
5.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Longduoduo Co (LDDD) has a Altman Z-Score of 5.38 as of Jun. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Longduoduo Co and its competitors. This is 94% below median its historical median of 93.31. Over the past decade, Longduoduo Co's Altman Z-Score has ranged from 5.38 to 555.83.
Is Longduoduo Co's Altman Z-Score too high?
Longduoduo Co's current Altman Z-Score of 5.38 is 94% below median its 10-year median of 93.31. Over the past 10 years, this metric has ranged from a low of 5.38 to a high of 555.83. The Medical Diagnostics & Research industry median Altman Z-Score is 2.35. Longduoduo Co's value of 5.38 is 128.9% above this industry median. Overall, Longduoduo Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Longduoduo Co's Altman Z-Score compare to AWHL and BIAF?
Longduoduo Co's Altman Z-Score of 5.38 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Altman Z-Score is 2.35. Longduoduo Co's value of 5.38 is 128.9% above this benchmark. Historically, Longduoduo Co's own Altman Z-Score has ranged from 5.38 to 555.83 over the past decade. While the company's 10-year median is 93.31 vs. the industry median of 2.35, Longduoduo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.35, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longduoduo Co's current Altman Z-Score of 5.38 is 128.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Longduoduo Co and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longduoduo Co's current Altman Z-Score is 5.38, which is 94% below median its own 10-year median of 93.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longduoduo Co stock overvalued right now?
Longduoduo Co (LDDD) has a current Altman Z-Score of 5.38. The stock's GF Value™ is $2.30, compared to a current price of $0.51 — trading 77.8% below its estimated fair value. The current Altman Z-Score is 5.38, which is 94% below median its 10-year median of 93.31 and 128.9% above the Medical Diagnostics & Research industry median of 2.35. Longduoduo Co's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Longduoduo Co (LDDD), the current Altman Z-Score is 5.38 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longduoduo Co (LDDD) Overvalued in 2026?
Based on GuruFocus' analysis, Longduoduo Co stock appears to be undervalued.
The current stock price of $0.51 is trading 77.8% below its estimated GF Value™ of $2.30.
Key valuation signals for LDDD:
Altman Z-Score: 5.38 (94% below median its 10-year median of 93.31)
GF Value™: $2.30 vs. price of $0.51 (77.8% below fair value)
Industry Position: 128.9% above the Medical Diagnostics & Research median
No single metric tells the full story. See the LDDD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longduoduo Co Ltd through its operating subsidiaries, is engaged in providing preventive healthcare solutions. It offers a wide range of comprehensive preventive healthcare services, including disease screening, healthcare treatments, healthcare products, and other related services. The company mainly focuses on the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases. Its revenues are mainly generated from customers in the People's Republic of China.
47GF Score
Get the complete analysis for LDDD
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LDDD has been successfully added to your 
